CFRXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CFRXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ContraFect has the GF Value Rank of 0.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of ContraFect's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Lishan Aklog | director | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171 |
Michael Messinger | officer: VP Finance | 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534 |
Cary Sucoff | director | 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904 |
David N. Low | director | EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111 |
Sol J Barer | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Lisa Ricciardi | director | C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
Joshua B Muntner | officer: SVP Business Development | 30 FIFTH AVENUE, 12F, NEW YORK NY 10011 |
Shanghai Fosun Pharmaceutical (group) Co., Ltd. | 10 percent owner | BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233 |
Fosun Industrial Co., Ltd | 10 percent owner | FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000 |
Cara M Cassino | officer: Chief Medical Officer | 757 STONY POINT ROAD, BENSON VT 05743 |
Natalie Bogdanos | officer: General Counsel | 207-23 DARREN DRIVE, BAYSIDE NY 11360 |
Roger Pomerantz | director | 711 HARVEST HILL ROAD, CHALFONT PA 18914 |
Michael J. Otto | director | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-25-2022
By Value_Insider Value_Insider • 12-19-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By Value_Insider Value_Insider • 11-28-2022
By sperokesalga sperokesalga • 04-26-2023
By PurpleRose PurpleRose • 07-15-2022
By Marketwired • 08-28-2023
By GuruFocusNews GuruFocusNews • 06-29-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.